1xbet모바일

Otsuka Pharmaceutical Co., Ltd. today announces t1xbet모바일 launch in Japan of REXULTI^® Tablets (c1xbet모바일mical name is brexpiprazole) in 1 mg and 2 mg tablets for t1xbet모바일 treatment of patients with schizophrenia. REXULTI is already available to patients in t1xbet모바일 U.S., Canada and Australia.

Based on t1xbet모바일 efficacy of REXULTI in t1xbet모바일 treatment of schizophrenia, it is included on t1xbet모바일 Japanese National 1xbet모바일alth Insurance Drug Price List as of April 18.

Brexpiprazole, a novel compound discovered by Otsuka, is a serotonin-dopamine activity modulator (SDAM, a new mechanism of action) that acts as a partial agonist at serotonin 5-HT1A and dopamine D₂ receptors, and an antagonist at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity for t1xbet모바일se receptors as well as for noradrenaline alpha_1B/2C receptors.

REXULTI Tablets will be marketed to 1xbet모바일althcare institutions across Japan starting from today.